CSL has used the first session of its capital markets fiesta in Chicago to assure investors the company has a flu vaccine ...

The ASX drifted lower by lunchtime as miners and tech fell again. Meanwhile, Michael Burry has resurfaced, with fresh shorts ...

Amid a slew of secondary equity raisings and at least two planned IPOs, the biotech sector is ending a difficult year on a ...

Older Australians who stop working but fail to inform their super funds of their retirement are paying 15 per cent tax on their super.

October was rough for Aussie tech, with Xero and WiseTech dragging the XIJ down 8pc, but behind the red ink a new crop of ...

The ASX 200 staved off a 90-point fall to shed just 11 points by trade-end after a strong rotation into defensive stocks.

The ASX 200 Health Care Index fell 4.83% in October and is now deep in red territory for 2025 as heavy CSL fall weighs on ...

Tryptamine Therapeutics (ASX:TYP) raises $6.1 million to advance its clinical trial for TRP-8803 for treating binge eating ...

Race Oncology, EZZ Life Science and Neurotech International are among ASX health companies reporting quarterly results.

The ASX biotech sector ran strongly in October, but the big-cap thoroughbreds found the track conditions more challenging.

ASX-listed tech companies have released their latest quarterly results, showing solid progress across key areas.

The executive team behind De Grey Mining has resurfaced, powering gains at the Richardson Street Group's Bellavista Resources ...